Report: Pharma Spent $120M on Lobbying Last Year
New federal disclosures revealed that 34 major pharmaceutical companies spent more than $120 million on lobbying last year, STAT reports. [...]
ISPOR Publishes Report Top 10 HEOR Trends
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) this week published its 2020 Top 10 HEOR Trends report. "As [...]
What Do Value Assessments Miss? Rethinking Value Using New Health Economics Evidence.
Dr. Patti Peeples, CEO and Founder of HealthEconomics.Com, recently sat down with Dr. Anupam Jena, Scientific Advisor, Precision Xtract, to discuss his latest research that expands the definition and measurement of value of novel therapies by using new health economics evidence.
CVS Caremark’s foray into cost-effectiveness analysis raises questions about the future of prescription medicines in America
Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, [...]
Drug Pricing Value Assessment Methods in the United States: The National Pharmaceutical Council Viewpoint
Swarali Tadwalkar, MPHIntern Written by Swarali Tadwalkar, MPH, Guest Blogger and Research Intern at HealthEconomics.Com Drug prices are the [...]
